Pulmonary arterial hypertension: MR imaging-derived first-pass bolus kinetic parameters are biomarkers for pulmonary hemodynamics, cardiacfunction, and ventricular remodeling

Radiology

Volumn 263, Issue 3, 2012, Pages 678-687

  Skrok, Jan ^a   Shehata, Monda L ^a   Mathai, Stephen ^a   Girgis, Reda E ^a   Zaiman, Ari ^a   Mudd, James O ^a   Boyce, Danielle ^a   Lechtzin, Noah ^a   Lima, João A C ^a   Bluemke, David A ^c   Hassoun, Paul M ^a   Vogel Claussen, Jens ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CARDIAC IMAGING; CARDIOPULMONARY FUNCTION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HEART CATHETERIZATION; HEART INDEX; HEART RIGHT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; HUMAN; LUNG ARTERY PRESSURE; LUNG CAPACITY; LUNG VASCULAR RESISTANCE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SURVIVAL PREDICTION;

EID: 84862486975     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12111001     Document Type: Article

References (35)

1. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association - developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119(16):2250-2294.
2. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 Suppl):78S-92S. (Pubitemid 38932344)
3. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182(2):252-260.
4. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009;120(11):992-1007.
5. Roeleveld RJ, Marcus JT, Boonstra A, et al. A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. J Magn Reson Imaging 2005;22(1):67-72. (Pubitemid 40885130)
6. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004;147(2):218-223. (Pubitemid 38176819)
7. Benza R, Biederman R, Murali S, Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 2008;52(21):1683-1692.
8. Jones RH, Sabiston DC Jr, Bates BB, Morris JJ, Anderson PA, Goodrich JK. Quantitative radionuclide angiocardiography for determination of chamber to chamber cardiac transit times. Am J Cardiol 1972;30(8): 855-864.
9. Selzer A, Dunlap RW, Wray HW, Russell J. A critical appraisal of the circulation time test. Arch Intern Med 1968;122(6):491-495.
10. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837-1847. (Pubitemid 28213628)
11. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356(1):39-46. (Pubitemid 46041752)
12. Levin JR, Serlin RC, Seaman MA. Controlled, powerful multi-comparison strategy for several situations. Psychol Bull 1994;115(1):153-159. (Pubitemid 24976741)
13. Fisher RA. The design of experiments. Edinburgh, Scotland: Oliver & Boyd, 1935.
14. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45(1):255-268.
15. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121(18):2045-2066.
16. Francois CJ, Shors SM, Bonow RO, Finn JP. Analysis of cardiopulmonary transit times at contrast material-enhanced MR imaging in patients with heart disease. Radiology 2003;227(2):447-452. (Pubitemid 36514760)
17. Shors SM, Cotts WG, Pavlovic-Surjancev B, François CJ, Gheorghiade M, Finn JP. Heart failure: evaluation of cardiopulmonary transit times with time-resolved MR angiography. Radiology 2003;229(3):743-748. (Pubitemid 37467579)
18. Cao JJ, Wang Y, McLaughlin J, et al. Prolonged pulmonary transit time by cardiac MRI is a marker of hemodynamic derangement in patients with congestive heart failure. J Cardiovasc Magn Reson 2010;12(Suppl 1):P96.
19. Goldman J, Cohen E, Rosenbluth A, Poon M. Contrast bolus MR transit time through the pulmonary circulation in pulmonary hypertension: a novel noninvasive index of pulmonary flow [abstr]. In: Proceedings of the Tenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2002; 403.
20. Lakoma A, Tuite D, Sheehan J, Weale P, Carr JC. Measurement of pulmonary circulation parameters using time-resolved MR angiography in patients after Ross procedure. AJR Am J Roentgenol 2010;194(4):912-919.
21. Sergiacomi G, Bolacchi F, Cadioli M, et al. Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement. Radiology 2010;254(2):601-608.
22. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006;114(17):1883-1891. (Pubitemid 44673364)
23. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179(2):151-157.
24. Mahapatra S, Nishimura RA, Oh JK, Mc-Goon MD. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr 2006;19(8):1045-1050. (Pubitemid 44118686)
25. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2006;47(4):799-803. (Pubitemid 43243104)
26. Mousseaux E, Tasu JP, Jolivet O, Simonneau G, Bittoun J, Gaux JC. Pulmonary arterial resistance: noninvasive measurement with indexes of pulmonary flow estimated at velocity-encoded MR imaging - preliminary experience. Radiology 1999;212(3):896-902. (Pubitemid 29410999)
27. Tardivon AA, Mousseaux E, Brenot F, et al. Quantification of hemodynamics in primary pulmonary hypertension with magnetic resonance imaging. Am J Respir Crit Care Med 1994;150(4):1075-1080. (Pubitemid 24318038)
28. Laffon E, Laurent F, Bernard V, De Boucaud L, Ducassou D, Marthan R. Noninvasive assessment of pulmonary arterial hypertension by MR phase-mapping method. J Appl Physiol 2001;90(6):2197-2202. (Pubitemid 32467412)
29. Alunni JP, Degano B, Arnaud C, et al. Cardiac MRI in pulmonary artery hypertension: correlations between morphological and functional parameters and invasive measurements. Eur Radiol 2010;20(5):1149-1159.
30. Frank H, Globits S, Glogar D, Neuhold A, Kneussl M, Mlczoch J. Detection and quantification of pulmonary artery hypertension with MR imaging: results in 23 patients. AJR Am J Roentgenol 1993;161(1):27-31. (Pubitemid 23208740)
31. Saba TS, Foster J, Cockburn M, Cowan M, Peacock AJ. Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure. Eur Respir J 2002;20(6):1519-1524. (Pubitemid 35460622)
32. Vogel-Claussen J, Shehata ML, Lossnitzer D, Skrok J, Bluemke DA, Hassoun PM. Increased right ventricular septomarginal trabeculation mass is a novel marker for pulmonary hypertension: comparison with ventricular mass index [abstr]. In: Radiological Society of North America scientific assembly and annual meeting program. Oak Brook, Ill: Radiological Society of North America, 2009; 617-618.
33. Ley S, Mereles D, Puderbach M, et al. Value of MR phase-contrast flow measurements for functional assessment of pulmonary arterial hypertension. Eur Radiol 2007;17(7):1892-1897. (Pubitemid 46909681)
34. Kreitner KF, Kunz RP, Weschler C, et al. Systematic analysis of the geometry of a defined contrast medium bolus: implications for contrast enhanced 3D MR-angiography of thoracic vessels [in German]. Rofo 2005;177(5):646-654.
35. Jalandhara N, Arora R, Batuman V. Nephrogenic systemic fibrosis and gadolinium- containing radiological contrast agents: an update. Clin Pharmacol Ther 2011;89(6):920-923.